Commentary: Reducing HIV-associated tuberculosis in children.
Boulle
Andrew
A
School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. andrew.boulle@uct.ac.za
Eley
Brian
B
D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D000995:Antitubercular Agents / Q000627:therapeutic use; D002648:Child; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors; D014376:Tuberculosis / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control*
D044966:Anti-Retroviral Agents; D000995:Antitubercular Agents; D007538:Isoniazid